Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FYU-981 (Dotinurad) in Elderly vs Non-Elderly
NCT02344875Phase 1Completed
- Sponsor
- Fuji Yakuhin
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dotinurad in hyperuricemia and gout (4 arms), sponsored by Fuji Yakuhin. Primary endpoints: Maximum plasma concentration at 48 hours, Time to reach the peak plasma concentration at 48 hours and 8 more. Started May 2014; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT02344875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02344875.